FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.
What happened
FDA inspected Apothecary Pharma's outsourcing facility—a compounder registered to make sterile drugs—from May 12 to May 15, 2025, and issued a Form 483 listing inspection findings. Investigators found sterile drug products made under insanitary conditions that could contaminate them, plus current good manufacturing practice (CGMP) failures. FDA also found some labels missing required ingredient and use information and adverse event reporting procedures inadequate.
What FDA found
Sterile drug products were prepared under insanitary conditions, including blocked sterile airflow, arms resting in the hood, unsanitized gloves, exposed skin, inadequate smoke studies, and rusty or hard-to-clean equipment.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The company did not establish or follow written responsibilities and procedures for its quality control unit.
21 CFR 211.22(d)The company did not establish and follow adequate written procedures to prevent microbial contamination, including validation of aseptic and sterilization processes.
21 CFR 211.113(b)The company did not ensure manufacturing personnel wore clothing appropriate to protect the drug product from contamination.
21 CFR 211.28(a)The company lacked adequate systems for maintaining equipment used to control aseptic conditions and for cleaning and disinfecting the room and equipment.
21 CFR 211.42(c)(10)(v), (vi)Labels for Tirzepatide Injection 10 mg/mL and Semaglutide Injection 2.5 mg/mL lacked a list of active and inactive ingredients, and some containers lacked adverse event reporting information and directions for use.
FDCA section 503B(a)(10) [21 U.S.C. § 353b(a)(10)]
What FDA wants
Within 15 working days, Apothecary Pharma must notify FDA in writing of the specific steps it has taken to address the violations, prevent recurrence, and include supporting documents; if it cannot complete the work, it must explain the delay and when it will finish. FDA also strongly recommends a comprehensive assessment of operations with a third-party consultant who has sterile drug manufacturing expertise.
Who should pay attention
- health systems and clinics that buy compounded sterile drugs
- compounding pharmacies and outsourcing facilities making sterile products
- providers or brands using compounded tirzepatide or semaglutide
This is a summary. Read the original letter on fda.gov.